ZA967513B - Method of treating insulin resistance. - Google Patents

Method of treating insulin resistance.

Info

Publication number
ZA967513B
ZA967513B ZA9607513A ZA967513A ZA967513B ZA 967513 B ZA967513 B ZA 967513B ZA 9607513 A ZA9607513 A ZA 9607513A ZA 967513 A ZA967513 A ZA 967513A ZA 967513 B ZA967513 B ZA 967513B
Authority
ZA
South Africa
Prior art keywords
insulin resistance
treating insulin
treating
resistance
insulin
Prior art date
Application number
ZA9607513A
Other languages
English (en)
Inventor
Carol Lynn Broderick
Mark Louis Heiman
Richard Dennis Dimarchi
Lawrence Edward Stramm
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA967513B publication Critical patent/ZA967513B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9607513A 1995-09-08 1996-09-05 Method of treating insulin resistance. ZA967513B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US347395P 1995-09-08 1995-09-08

Publications (1)

Publication Number Publication Date
ZA967513B true ZA967513B (en) 1998-03-05

Family

ID=21706036

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9607513A ZA967513B (en) 1995-09-08 1996-09-05 Method of treating insulin resistance.

Country Status (7)

Country Link
US (1) US5939387A (xx)
EP (1) EP0766966A3 (xx)
JP (1) JPH11512395A (xx)
AU (1) AU7236696A (xx)
CA (1) CA2230968A1 (xx)
WO (1) WO1997009060A1 (xx)
ZA (1) ZA967513B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165127A1 (en) * 1996-12-24 2002-11-07 Supergen, Inc. Methods for treating insulin resistance and identifying patients at risk for the disease
ATE356139T1 (de) 1997-06-25 2007-03-15 Pfizer Dipeptidderivate zur förderung der sekretion von wachstumshormon
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
EP1007085B1 (en) * 1997-07-04 2001-11-21 Pharmacia Aktiebolag Use of growth hormone in compositions for treating insulin resistance in the heart
AU766305B2 (en) 1998-01-16 2003-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
SE0000837D0 (sv) * 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
AU2003229222B2 (en) * 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
DE60336934D1 (de) 2003-10-03 2011-06-09 Veijlen N V Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten
WO2006014798A2 (en) * 2004-07-27 2006-02-09 Mount Sinai School Of Medicine Methods and compositions for using sax2
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
EP2413967A1 (en) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Treatment of insulin-resistant disorders
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
ES2817877T3 (es) 2012-02-15 2021-04-08 Aileron Therapeutics Inc Macrociclos peptidomiméticos
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
ZA922746B (en) * 1991-04-26 1992-12-30 Lilly Co Eli Superactive grf analogs
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues

Also Published As

Publication number Publication date
AU7236696A (en) 1997-03-27
CA2230968A1 (en) 1997-03-13
US5939387A (en) 1999-08-17
JPH11512395A (ja) 1999-10-26
EP0766966A2 (en) 1997-04-09
EP0766966A3 (en) 2001-02-28
WO1997009060A1 (en) 1997-03-13

Similar Documents

Publication Publication Date Title
ZA967513B (en) Method of treating insulin resistance.
PL324284A1 (en) Methods of treating diabetes
ZA961316B (en) Benzopyran-containing compounds and method for their use.
PH30791A (en) Fibre treatment method.
AU1967897A (en) Method for treatment of insulin resistance
ZA985546B (en) Treatment of insulin resistance.
ZA986363B (en) Novel method of treatment.
EP0832204A4 (en) TREATMENT OF INSULIN RESISTANCE
ZA985237B (en) Novel method of treatment.
ZA921107B (en) Method of treating Type I diabetes.
EP0630383A4 (en) METHODS OF TREATING DIABETES.
GB9605828D0 (en) Treatment method
ZA966603B (en) Therapeutic method.
ZA986364B (en) Novel method of treatment.
IL124786A0 (en) Method for treating pain
ZA986365B (en) Novel method of treatment.
ZA977867B (en) Method of treatment.
GB9714841D0 (en) Treatment method
ZA965939B (en) Method of treating epilepsy.
ZA966970B (en) Water treatment method.
GB9507825D0 (en) Method of treatment
ZA963472B (en) Method of treatment.
GB9513129D0 (en) Treatment method
GB9513130D0 (en) Treatment method
GB9511594D0 (en) Treatment method